<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39350371</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2426-0266</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>5</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>The journal of prevention of Alzheimer's disease</Title><ISOAbbreviation>J Prev Alzheimers Dis</ISOAbbreviation></Journal><ArticleTitle>Japanese Subgroup Analyses from EMERGE and ENGAGE, Phase 3 Clinical Trials of Aducanumab in Patients with Early Alzheimer's Disease.</ArticleTitle><Pagination><StartPage>1260</StartPage><EndPage>1269</EndPage><MedlinePgn>1260-1269</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.14283/jpad.2024.106</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Global prevalence and incidence of dementia continue to rise at a rapid rate. There is a need for new Alzheimer's disease (AD) treatments globally. Aducanumab is a human monoclonal antibody that selectively targets aggregated soluble amyloid beta oligomers and insoluble amyloid beta fibrils. In June 2021, aducanumab was approved by the US Food and Drug Administration for the treatment of AD under the accelerated approval pathway.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">We evaluated the efficacy, safety, biomarker and pharmacokinetics (PK) of aducanumab in Japanese subgroups in EMERGE and ENGAGE studies.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">EMERGE and ENGAGE were two randomized, double-blind, placebo-controlled, global, phase 3 studies of aducanumab in patients with early AD (mild cognitive impairment due to AD or mild AD dementia).</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">These studies involved 348 sites in 20 countries.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Participants enrolled in Japan included 121 (7.4% of total 1638 in EMERGE) and 100 (6.1% of total 1647 in ENGAGE) patients (aged 50-85 years with confirmed amyloid pathology) who met clinical criteria for mild cognitive impairment due to AD or mild AD dementia.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Participants were randomly assigned 1:1:1 to receive aducanumab low dose (3 or 6 mg/kg target dose), high dose (6 or 10 mg/kg target dose) or placebo via IV infusion once every 4 weeks over 76 weeks.</AbstractText><AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">The primary outcome measure was change from baseline to Week 78 on the Clinical Dementia Rating Sum of Boxes (CDR-SB), an integrated scale that assesses both function and cognition. Other measures included safety assessments; secondary and tertiary clinical outcomes that assessed cognition, function, and behavior; biomarker endpoints (amyloid PET and plasma p-tau181); serum PK profiles and immunogenicity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Results from the Japanese subgroup analyses were generally consistent with those of the overall study population across endpoints, while a lower mean body weight (kg) and a smaller proportion of ApoE ε4 carriers were observed in the Japanese subgroup population. A treatment effect was observed in favor of aducanumab on the primary and secondary efficacy endpoints at Week 78 in EMERGE, but not ENGAGE. The incidence and type of adverse events in the Japanese subgroups were generally comparable to those observed in the overall study population; amyloid related imaging abnormalities (ARIA) were common treatment-related adverse events that appeared to be related to the aducanumab dose. ARIA incidence was generally lower in the Japanese subgroup compared with the overall population. Consistent with the overall data set, a robust dose-dependent decrease in amyloid beta levels as assessed with amyloid-PET and plasma p-tau181 was observed. Serum PK profiles and immunogenicity of aducanumab in Japanese population were consistent with the non-Japanese population.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Efficacy, safety, biomarker, and PK profiles of aducanumab were consistent between the Japanese subgroup and the overall population. A positive treatment effect of aducanumab on efficacy endpoints was observed in EMERGE, but not in ENGAGE.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Toda</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Yasuo Toda, Biogen Japan Ltd., 1-4-1 Nihonbashi, Chuo-ku, Tokyo 103-0027, Email: yasuo.toda@biogen.com, Phone: +81-3-3275-2074, Fax: +81-3-3275-1920, ORCID: 0000-0002-8737-5256.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwatsubo</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Matsuda</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Miyata</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kuribayashi</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Hughes</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Muralidharan</LastName><ForeName>K K</ForeName><Initials>KK</Initials></Author><Author ValidYN="Y"><LastName>Rubel</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Hutchison</LastName><ForeName>R M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Budd Haeberlein</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Prev Alzheimers Dis</MedlineTA><NlmUniqueID>101638820</NlmUniqueID><ISSNLinking>2274-5807</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>105J35OE21</RegistryNumber><NameOfSubstance UI="C000600266">aducanumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="Y">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000095225" MajorTopicYN="N">East Asian People</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aducanumab</Keyword><Keyword MajorTopicYN="N">Japan</Keyword><Keyword MajorTopicYN="N">PK</Keyword><Keyword MajorTopicYN="N">amyloid beta</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">early Alzheimer’s disease</Keyword><Keyword MajorTopicYN="N">immunogenicity</Keyword><Keyword MajorTopicYN="N">plasma p-tau181</Keyword><Keyword MajorTopicYN="N">subgroup analyses</Keyword></KeywordList><CoiStatement>YN did not receive any fees or special compensation from Biogen in return for authoring this publication. TC, YT, RH, KKM, CR and RMH are employees and shareholders of Biogen Inc. YT, MM, MJ, KK and JY are employees of Biogen Japan Ltd and shareholders of Biogen Inc. NM was an employee of Biogen Japan Ltd at the time of this study and has since left the company. SBH was an employee of Biogen Inc at the time of this study and has since left the company and is an employee of Enigma Biomedical Group USA.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39350371</ArticleId><ArticleId IdType="pmc">PMC11436400</ArticleId><ArticleId IdType="doi">10.14283/jpad.2024.106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Organization WH. Risk reduction of cognitive decline and dementia: WHO guidelines. 2019</Citation><ArticleIdList><ArticleId IdType="pubmed">31219687</ArticleId></ArticleIdList></Reference><Reference><Citation>2021 Alzheimer’s disease facts and figures. Alzheimers Dement. Mar 2021;17(3):327–406. doi:10.1002/alz.12328</Citation><ArticleIdList><ArticleId IdType="pubmed">33756057</ArticleId></ArticleIdList></Reference><Reference><Citation>Muramatsu N, Akiyama H. Japan: super-aging society preparing for the future. Gerontologist. Aug 2011;51(4):425–32. doi:10.1093/geront/gnr067</Citation><ArticleIdList><ArticleId IdType="pubmed">21804114</ArticleId></ArticleIdList></Reference><Reference><Citation>Collaborators GBDD. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. Jan 2019;18(1):88–106. doi:10.1016/S1474-4422(18)30403-4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6291454</ArticleId><ArticleId IdType="pubmed">30497964</ArticleId></ArticleIdList></Reference><Reference><Citation>Montgomery W, Ueda K, Jorgensen M, Stathis S, Cheng Y, Nakamura T. Epidemiology, associated burden, and current clinical practice for the diagnosis and management of Alzheimer’s disease in Japan. Clinicoecon Outcomes Res. 2018;10:13–28. doi:10.2147/CEOR.S146788</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5749549</ArticleId><ArticleId IdType="pubmed">29343976</ArticleId></ArticleIdList></Reference><Reference><Citation>Sado M, Ninomiya A, Shikimoto R, et al. The estimated cost of dementia in Japan, the most aged society in the world. PLoS One. 2018;13(11):e0206508. doi:10.1371/journal.pone.0206508</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6231619</ArticleId><ArticleId IdType="pubmed">30418983</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno S, Chen Y, Sakamaki H, Matsumaru N, Yoshino M, Tsukamoto K. Humanistic burden among caregivers of patients with Alzheimer’s disease or dementia in Japan: a large-scale cross-sectional survey. J Med Econ. Jan–Dec 2021;24(1):181–192. doi:10.1080/13696998.2021.1877149</Citation><ArticleIdList><ArticleId IdType="pubmed">33467967</ArticleId></ArticleIdList></Reference><Reference><Citation>Igarashi A, Azuma MK, Zhang Q, et al. Predicting the Societal Value of Lecanemab in Early Alzheimer’s Disease in Japan: A Patient-Level Simulation. Neurol Ther. Aug 2023;12(4):1133–1157. doi:10.1007/s40120-023-00492-7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10310671</ArticleId><ArticleId IdType="pubmed">37188886</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotz J, Halliday G, Nisbet RM. Molecular Pathogenesis of the Tauopathies. Annu Rev Pathol. Jan 24 2019;14:239–261. doi:10.1146/annurev-pathmechdis-012418-012936</Citation><ArticleIdList><ArticleId IdType="pubmed">30355155</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Morstorf T, Zhong K. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2014;6(4):37. doi:10.1186/alzrt269</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4095696</ArticleId><ArticleId IdType="pubmed">25024750</ArticleId></ArticleIdList></Reference><Reference><Citation>Logovinsky V, Satlin A, Lai R, et al. Safety and tolerability of BAN2401—a clinical study in Alzheimer’s disease with a protofibril selective Abeta antibody. Alzheimers Res Ther. Apr 6 2016;8(1):14. doi:10.1186/s13195-016-0181-2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4822297</ArticleId><ArticleId IdType="pubmed">27048170</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in Early Alzheimer’s Disease. N Engl J Med. May 6 2021;384(18):1691–1704. doi:10.1056/NEJMoa2100708</Citation><ArticleIdList><ArticleId IdType="pubmed">33720637</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. Jun 2016;8(6):595–608. doi:10.15252/emmm.201606210</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4888851</ArticleId><ArticleId IdType="pubmed">27025652</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny J, Chiao P, Bussiere T, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer’s disease. Nature. Sep 1 2016;537(7618):50–6. doi:10.1038/nature19323</Citation><ArticleIdList><ArticleId IdType="pubmed">27582220</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolar M, Abushakra S, Hey JA, Porsteinsson A, Sabbagh M. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval. Alzheimers Res Ther. Aug 12 2020;12(1):95. doi:10.1186/s13195-020-00663-w</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7424995</ArticleId><ArticleId IdType="pubmed">32787971</ArticleId></ArticleIdList></Reference><Reference><Citation>ADUHELM (aducanumab) [prescribing information]. Cambridge, MA: Biogen, Inc. 2021.</Citation></Reference><Reference><Citation>Linse S, Scheidt T, Bernfur K, et al. Kinetic fingerprints differentiate the mechanisms of action of anti-Abeta antibodies. Nat Struct Mol Biol. Dec 2020;27(12):1125–1133. doi:10.1038/s41594-020-0505-6</Citation><ArticleIdList><ArticleId IdType="pubmed">32989305</ArticleId></ArticleIdList></Reference><Reference><Citation>ClinicalTrials.gov. 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer’s Disease (ENGAGE) [NCT02477800]. Accessed April 21, 2021. https://clinicaltrials.gov/ct2/show/NCT02477800</Citation></Reference><Reference><Citation>ClinicalTrials.gov. 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer’s Disease (EMERGE) [NCT02484547]. Accessed April 21, 2021. https://clinicaltrials.gov/ct2/show/NCT02484547</Citation></Reference><Reference><Citation>Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease. J Prev Alzheimers Dis. 2022;9(2):197–210. doi:10.14283/jpad.2022.30</Citation><ArticleIdList><ArticleId IdType="pubmed">35542991</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallinckrodt C, Tian Y, Aisen PS, et al. Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab. J Prev Alzheimers Dis. 2023;10(2):171–177. doi:10.14283/jpad.2023.6</Citation><ArticleIdList><ArticleId IdType="pubmed">36946443</ArticleId></ArticleIdList></Reference><Reference><Citation>National Research Council (US) Panel on Race E, and Health in Later Life. Ethnic Differences in Dementia and Alzheimer’s Disease. In: Anderson NB BR, Cohen B, editors, ed. Critical Perspectives on Racial and Ethnic Differences in Health in Late Life. National Academies Press (US); 2004:chap 4.</Citation><ArticleIdList><ArticleId IdType="pubmed">20669464</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwatsubo T, Iwata A, Suzuki K, et al. Japanese and North American Alzheimer’s Disease Neuroimaging Initiative studies: Harmonization for international trials. Alzheimers Dement. Aug 2018;14(8):1077–1087. doi:10.1016/j.jalz.2018.03.009</Citation><ArticleIdList><ArticleId IdType="pubmed">29753531</ArticleId></ArticleIdList></Reference><Reference><Citation>Eto M, Watanabe K, Ishii K. A racial difference in apolipoprotein E allele frequencies between the Japanese and Caucasian populations. Clin Genet. Nov 1986;30(5):422–7. doi:10.1111/j.1399-0004.1986.tb01901.x</Citation><ArticleIdList><ArticleId IdType="pubmed">3802561</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings J, Reynders R, Zhong K. Globalization of Alzheimer’s disease clinical trials. Alzheimers Res Ther. Aug 17 2011;3(4):24. doi:10.1186/alzrt86</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3226279</ArticleId><ArticleId IdType="pubmed">21861855</ArticleId></ArticleIdList></Reference><Reference><Citation>Grill JD, Raman R, Ernstrom K, et al. Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer’s disease clinical trials. Alzheimers Res Ther. 2015;7(1):39. doi:10.1186/s13195-015-0122-5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4481112</ArticleId><ArticleId IdType="pubmed">26120368</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. May 2011;7(3):270–9. doi:10.1016/j.jalz.2011.03.008</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. May 2011;7(3):263–9. doi:10.1016/j.jalz.2011.03.005</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, Chalkias S, Barkhof F, et al. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease. JAMA Neurol. Jan 1 2022;79(1):13–21. doi:10.1001/jamaneurol.2021.4161</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8609465</ArticleId><ArticleId IdType="pubmed">34807243</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevigny J, Suhy J, Chiao P, et al. Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials: Experience in a Phase 1b Clinical Trial. Alzheimer Dis Assoc Disord. Jan-Mar 2016;30(1):1–7. doi:10.1097/WAD.0000000000000144</Citation><ArticleIdList><ArticleId IdType="pubmed">26885819</ArticleId></ArticleIdList></Reference><Reference><Citation>Amyvid (Florbetapir F 18 Injection) [prescribing information]. Indianapolis, IN: Eli Lilly &amp; Co. 2012.</Citation></Reference><Reference><Citation>VIZAMYL (flutemetamol F 18 injection) [prescribing information]. Dublin, OH: Cardinal Health. 2013.</Citation></Reference><Reference><Citation>Klunk WE, Koeppe RA, Price JC, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. Jan 2015;11(1):1–15e1–4. doi:10.1016/j.jalz.2014.07.003</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4300247</ArticleId><ArticleId IdType="pubmed">25443857</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpenter CL, Yan E, Chen S, et al. Body fat and body-mass index among a multiethnic sample of college-age men and women. J Obes. 2013;2013:790654. doi:10.1155/2013/790654</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3649342</ArticleId><ArticleId IdType="pubmed">23691288</ArticleId></ArticleIdList></Reference><Reference><Citation>Kagawa M, Kerr D, Uchida H, Binns CW. Differences in the relationship between BMI and percentage body fat between Japanese and Australian-Caucasian young men. Br J Nutr. May 2006;95(5):1002–7. doi:10.1079/bjn20061745</Citation><ArticleIdList><ArticleId IdType="pubmed">16611393</ArticleId></ArticleIdList></Reference><Reference><Citation>Shai I, Jiang R, Manson JE, et al. Ethnicity, obesity, and risk of type 2 diabetes in women: a 20-year follow-up study. Diabetes Care. Jul 2006;29(7):1585–90. doi:10.2337/dc06-0057</Citation><ArticleIdList><ArticleId IdType="pubmed">16801583</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R, Salloway S, Brooks DJ, et al. Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. Mar 2012;11(3):241–9. doi:10.1016/S1474-4422(12)70015-7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4063417</ArticleId><ArticleId IdType="pubmed">22305802</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrowitzki S, Lasser RA, Dorflinger E, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease. Alzheimers Res Ther. Dec 8 2017;9(1):95. doi:10.1186/s13195-017-0318-y</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5723032</ArticleId><ArticleId IdType="pubmed">29221491</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. Jan 23 2014;370(4):322–33. doi:10.1056/NEJMoa1304839</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159618</ArticleId><ArticleId IdType="pubmed">24450891</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Jack CR, Jr., Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement. Jul 2011;7(4):367–85. doi:10.1016/j.jalz.2011.05.2351</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3693547</ArticleId><ArticleId IdType="pubmed">21784348</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>